Charles Schwab’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.46M | Buy |
321,154
+10,560
| +3% | +$175K | ﹤0.01% | 2432 |
|
|
2026
Q1 | $5.04M | Sell |
310,594
-2,700
| -0.9% | -$47.8K | ﹤0.01% | 2402 |
|
|
2025
Q4 | $5.86M | Sell |
313,294
-6,850
| -2% | -$114K | ﹤0.01% | 2375 |
|
|
2025
Q3 | $4.67M | Buy |
320,144
+16,257
| +5% | +$205K | ﹤0.01% | 2469 |
|
|
2025
Q2 | $3.35M | Buy |
303,887
+16,171
| +6% | +$157K | ﹤0.01% | 2497 |
|
|
2025
Q1 | $2.57M | Sell |
287,716
-6,220
| -2% | -$57.9K | ﹤0.01% | 2532 |
|
|
2024
Q4 | $2.77M | Buy |
293,936
+2,060
| +0.7% | +$18.7K | ﹤0.01% | 2577 |
|
|
2024
Q3 | $2.35M | Buy |
291,876
+610
| +0.2% | +$5.28K | ﹤0.01% | 2658 |
|
|
2024
Q2 | $2.47M | Sell |
291,266
-19,235
| -6% | -$174K | ﹤0.01% | 2630 |
|
|
2024
Q1 | $2.79M | Sell |
310,501
-3,510
| -1% | -$32.5K | ﹤0.01% | 2503 |
|
|
2023
Q4 | $3.53M | Sell |
314,011
-14,166
| -4% | -$143K | ﹤0.01% | 2456 |
|
|
2023
Q3 | $2.83M | Sell |
328,177
-75,282
| -19% | -$727K | ﹤0.01% | 2493 |
|
|
2023
Q2 | $4.18M | Sell |
403,459
-79,413
| -16% | -$877K | ﹤0.01% | 2305 |
|
|
2023
Q1 | $5.24M | Sell |
482,872
-33,516
| -6% | -$354K | ﹤0.01% | 2183 |
|
|
2022
Q4 | $5.79M | Sell |
516,388
-8,528
| -2% | -$89.6K | ﹤0.01% | 2143 |
|
|
2022
Q3 | $5.32M | Buy |
524,916
+21,439
| +4% | +$201K | ﹤0.01% | 2188 |
|
|
2022
Q2 | $4.56M | Buy |
503,477
+100,837
| +25% | +$929K | ﹤0.01% | 2223 |
|
|
2022
Q1 | $3.85M | Buy |
402,640
+12,095
| +3% | +$119K | ﹤0.01% | 2398 |
|
|
2021
Q4 | $4.32M | Buy |
390,545
+38,752
| +11% | +$338K | ﹤0.01% | 2423 |
|
|
2021
Q3 | $2.6M | Sell |
351,793
-4,751
| -1% | -$53.1K | ﹤0.01% | 2637 |
|
|
2021
Q2 | $5.18M | Buy |
356,544
+23,060
| +7% | +$433K | ﹤0.01% | 2336 |
|
|
2021
Q1 | $6.81M | Buy |
333,484
+9,906
| +3% | +$188K | ﹤0.01% | 2149 |
|
|
2020
Q4 | $5.75M | Buy |
323,578
+10,014
| +3% | +$180K | ﹤0.01% | 2148 |
|
|
2020
Q3 | $4.64M | Sell |
313,564
-646
| -0.2% | -$12.1K | ﹤0.01% | 2096 |
|
|
2020
Q2 | $6.6M | Buy |
314,210
+14,634
| +5% | +$376K | ﹤0.01% | 1895 |
|
|
2020
Q1 | $6.92M | Buy |
299,576
+31,476
| +12% | +$788K | ﹤0.01% | 1661 |
|
|
2019
Q4 | $6.94M | Buy |
268,100
+9,237
| +4% | +$180K | ﹤0.01% | 1850 |
|
|
2019
Q3 | $5.04M | Buy |
258,863
+6,869
| +3% | +$139K | ﹤0.01% | 1955 |
|
|
2019
Q2 | $4.12M | Buy |
251,994
+13,042
| +5% | +$264K | ﹤0.01% | 2068 |
|
|
2019
Q1 | $5.42M | Buy |
238,952
+4,070
| +2% | +$103K | ﹤0.01% | 1949 |
|
|
2018
Q4 | $6.01M | Sell |
234,882
-1,978
| -0.8% | -$53.4K | ﹤0.01% | 1801 |
|
|
2018
Q3 | $7.74M | Buy |
236,860
+10,592
| +5% | +$289K | 0.01% | 1796 |
|
|
2018
Q2 | $5.13M | Buy |
226,268
+17,193
| +8% | +$408K | ﹤0.01% | 1986 |
|
|
2018
Q1 | $5.07M | Buy |
209,075
+9,398
| +5% | +$258K | ﹤0.01% | 1935 |
|
|
2017
Q4 | $5.57M | Buy |
199,677
+8,119
| +4% | +$240K | ﹤0.01% | 1879 |
|
|
2017
Q3 | $6.56M | Buy |
191,558
+14,241
| +8% | +$466K | 0.01% | 1735 |
|
|
2017
Q2 | $7.07M | Buy |
177,317
+14,709
| +9% | +$566K | 0.01% | 1596 |
|
|
2017
Q1 | $5.99M | Buy |
162,608
+17,136
| +12% | +$547K | 0.01% | 1652 |
|
|
2016
Q4 | $4.64M | Buy |
145,472
+26,088
| +22% | +$809K | 0.01% | 1788 |
|
|
2016
Q3 | $4.33M | Buy |
119,384
+5,734
| +5% | +$160K | 0.01% | 1741 |
|
|
2016
Q2 | $2.58M | Buy |
113,650
+29,512
| +35% | +$637K | ﹤0.01% | 1939 |
|
|
2016
Q1 | $1.58M | Sell |
84,138
-5,136
| -6% | -$84K | ﹤0.01% | 2167 |
|
|
2015
Q4 | $1.46M | Buy |
89,274
+15,258
| +21% | +$242K | ﹤0.01% | 2223 |
|
|
2015
Q3 | $814K | Buy |
74,016
+4,823
| +7% | +$61.4K | ﹤0.01% | 2451 |
|
|
2015
Q2 | $901K | Buy |
69,193
+2,152
| +3% | +$33.4K | ﹤0.01% | 2457 |
|
|
2015
Q1 | $1.16M | Buy |
67,041
+3,162
| +5% | +$58K | ﹤0.01% | 2318 |
|
|
2014
Q4 | $954K | Buy |
63,879
+2,133
| +3% | +$37.2K | ﹤0.01% | 2366 |
|
|
2014
Q3 | $1.42M | Buy |
61,746
+1,361
| +2% | +$39.5K | ﹤0.01% | 2143 |
|
|
2014
Q2 | $1.93M | Buy |
+60,385
| New | +$1.82M | ﹤0.01% | 2005 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
Charles Schwab's TBPH Position: Q2 2026 in Review
Charles Schwab increased its Theravance Biopharma (TBPH) stake by 3.4% in Q2 2026, buying an estimated $175K and bringing the position to 321,154 shares worth $5.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2432.
Charles Schwab first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $7.74M in Q3 2018. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.
- Charles Schwab held 321,154 shares of Theravance Biopharma worth $5.46M as of Q2 2026.
- Charles Schwab bought 10,560 Theravance Biopharma shares in Q2 2026, an estimated $175K.
- Theravance Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2432 holding.
- Charles Schwab first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
- Charles Schwab's Theravance Biopharma position peaked at $7.74M in Q3 2018.
- 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.